Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Up 29.2% in November

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 6,910,000 shares, a growth of 29.2% from the October 31st total of 5,350,000 shares. Based on an average daily volume of 1,460,000 shares, the short-interest ratio is presently 4.7 days.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Guggenheim decreased their price target on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Mizuho decreased their target price on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. StockNews.com lowered Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, HC Wainwright decreased their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $2.79.

Adaptimmune Therapeutics Stock Performance

Shares of NASDAQ ADAP opened at $0.72 on Monday. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The firm’s 50-day moving average price is $0.80 and its two-hundred day moving average price is $1.00. Adaptimmune Therapeutics has a 52-week low of $0.43 and a 52-week high of $2.05. The stock has a market capitalization of $184.41 million, a P/E ratio of -3.28 and a beta of 2.26.

Institutional Trading of Adaptimmune Therapeutics

Hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its position in Adaptimmune Therapeutics by 28.3% in the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after buying an additional 394,566 shares during the period. Long Focus Capital Management LLC increased its holdings in shares of Adaptimmune Therapeutics by 15.6% in the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock worth $12,037,000 after acquiring an additional 1,662,184 shares during the period. Vontobel Holding Ltd. lifted its position in Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 30,000 shares during the last quarter. Fullcircle Wealth LLC acquired a new position in Adaptimmune Therapeutics during the 3rd quarter valued at about $33,000. Finally, GSA Capital Partners LLP bought a new position in Adaptimmune Therapeutics in the 3rd quarter worth about $95,000. Institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.